bluuebunny/crossref_metadata_2025_split huggingface dataset:
Abnormal visual‐evoked potentials in leukemic children after cranial radiation
Authors: Russo Antonio , Tomarchio Salvatore , Pero Giuseppe , Consoli Giuseppe , Marina Roberto , Rizzari Carmelo , Schilirò Gino 
Published: February 2007

AbstractVisual‐evoked potentials (VEPs) were studied in 55 asymptomatic children with leukemia or solid tumors in remission in order to detect subclinical demyelination of the optic pathway after CNS prophylaxis. In group I (11 patients with ALL studied prospectively), VEP latency was increased in ten after cranial radiation (CR) as compared with previous values. Group II (18 patients with ALL in maintenance) and group III (16 patients with ALL off therapy) were studied retrospectively and VEP latency was found above normal limits in 33 and 31%, respectively. In group IV (four patients with solid tumors and six with leukemia, all of whom received no CR), VEP latency was normal despite periodical intrathecal methotrexate administrations to five of them. We conclude that CR determines a slowing of conduction on VEP test, probably due to demyelination of the optic pathway, in a high proportion of patients. The future clinical significance of these findings must be established throughout a prolonged follow‐up period.
Risk factors in long‐term sequelae of central nervous system prophylaxis in successfully treated children with acute lymphocytic leukemia
Authors: Carli M. , Perilongo G. , Laverda A. M. , Drigo P. , Casara G. L. , Marin G. , Sotti G. , Deambrosis G. , Zanesco L. 
Published: February 2007

AbstractSeventy‐two successfully treated patients with acute lymphocytic leukemia, all in first complete remission and all off therapy, who had received CNS prophylaxis (radiotherapy, 2,400 rad, plus intrathecal methotrexate), were studied by computed tomography (CD of the brain, EEGs, and neurologic evaluations 3 to 9 years after the end of prophylaxis. Thirty‐five patients showed CT brain scan abnormalities: intracranial calcifications (twelve); widening of the subarachnoid spaces (eight); isolated dilatation of ventricular spaces (three) and with frontal periventricular hypodensity (two); dilatation of ventricular and subarachnoid spaces (nine); and a hypodense area (one). Only 17 patients showed aspecific EEC abnormalities which were never linked to CT scan findings. None of our patients presented major motor deficits at the neurologic examination.A stepwise logistic regression technique showed that age less than 5 years at the time of prophylaxis was the most important risk factor (p = 0.008) of CT brain scan abnormalities followed by neurets (p = 0.037) and sex (p = 0.10). Furthermore, the multivariate analysis pointed out that the interactions between these variables were not significant and the effects were only of the first order.
Leukemic iris infiltration as the only site of relapse in a child with acute lymphoblastic leukemia: Temporary remission with high‐dose chemotherapy
Authors: Behrendt H. , Wenniger‐Prick L. M. d. B. 
Published: February 2007

AbstractA 12‐year‐old Caucasian boy developed leukemic hyphema with iris infiltration as the only relapse site during the third complete remission of his acute lymphoblastic leukemia. With high‐dose methotrexate, high‐dose cytosine‐arabinoside plus teniposide, and a 5‐week course of vincristine, prednisolone, and L‐asparaginase, a complete remission could be achieved. Maintenance treatment was reinstituted for 1 year. However, after stopping the treatment, the iris infiltrate reappeared, and this time the eye was irradiated after chemotherapeutic reinduction. Seven months later, the boy remains in complete remission. The pathogenesis of leukemic iris infiltration is discussed briefly.
Infantile lymphoblastic leukemia with(4;11) and septate uterus, double cervix, and double vagina: Case report and review of the literature
Authors: Morrow Robert C. , Dickerman Joseph D. , Clemmons Jackson J. 
Published: February 2007

AbstractTranslocation between chromosomes 4 and 11 has been associated with an aggressive subtype of acute lymphoblastic leukemia. To date, 32 cases have been reported, 12 of which have been in infants. We report the 13th infantile case and the first associated with a somatic abnormality (septate uterus with double cervix and double vagina).
Extravasation of dactinomycin, vincristine, and cisplatin: Studies in an animal model
Authors: Buchanan George R. , Buchsbaum Herbert J. , O'Banion Kathleen , Gojer Bernard 
Published: February 2007

AbstractExtravasation of some cytotoxic drugs results in chemical cellulitis. Management of suspected extravasation has been empiric and difficult to evaluate clinically. We investigated dactinomycin, vincristine, and cisplatin by means of intradermal injections in Balb‐c mice. Reproducible skin lesions with concentric areas of induration, erythema, and ulcer‐ation developed in a time‐ and dose‐dependent fashion following injection of dactinomycin. Vincristine caused no lesions following initial intradermal administration, but repeat injection 7 days later was followed by a diffuse punctate ulcerative lesion suggesting a hypersensitivity reaction. Three concentrations (1.0, 0.1, and 0.01 mg/ml) of cisplatin elicited cellulitis following initial injection, but there was no correlation between lesion size and dose. Injection of saline, hydrocortisone, ascorbic acid, sodium thiosulfate, buffered DNA solution, and beta adrenergic agonists and antagonists after the injection of dactinomycin failed to prevent development of lesions. Heat application was also ineffective; however, local cold application prevented or markedly reduced reactions to dactinomycin. We conclude that the intradermal mouse model may be appropriate for the evaluation of the three drugs studied and that cold application is the best antidote among those tested fordactinomycin‐induced ulceration in this model.
Homer's syndrome: An unusual presentation of Hodgkin's disease
Authors: Simon Sheryl R. , Dorighi John A. , Branda Richard F. , Ershler William B. 
Published: February 2007

AbstractHorner's Syndrome (ptosis, anisocoria, and anhydrosis) developed in a 22‐year‐old woman. A mediastinal mass was noted on chest x‐ray. Further evaluation led to a diagnosis of Hodgkin's disease, nodular sclerosis type. Horner's syndrome is an unusual initial manifestation of Hodgkin's disease, and, in this case, it was due to oculosympathetic damage from mediastinal compression. Because the potential for cure is high in Hodgkin's disease, this diagnosis should be considered in patients presenting with Horner's syndrome.
Treatment and outcome of undifferentiated carcinoma of the nasopharynx in childhood: A 13‐year experience
Authors: Lobo‐Sanahuja Francisco , Garcia Ivette , Carranza Alfonso , Camacho Alvaro 
Published: February 2007

AbstractBetween 1970 and 1983, 22 pediatric patients diagnosed as having undifferentiated nasopharyngeal carcinoma (UNC) were treated at the National Children's Hospital of Costa Rica; primary tumor with local extension (T3‐T4) was present in 45% of the patients, and metastasis of the cervical nodes (N1‐N3) in 82%. Patients were divided into groups A and B according to the type of treatment received. A description of both groups is as follows.Ten patients were treated with 5,000 to 6,000 rads tumor dose to the primary and a 5,125‐rad dose was administered to the lower neck between 1970 and 1977 (group A). Six patients received postradiation therapy with cyclophosphamide and vincristine and two patients also received 5‐fluorouracil. The outcome in group A was as follows: four (40%) failed to respond, six (60%) achieved full remission initially with two subsequent relapses, and the remaining four are still alive and free of relapse after 90 to 160 months (average 130) (two were treated with Co60 alone and two with chemotherapy.Twelve patients were treated with chemotherapy pre‐ and postradiation with CPM and adriamycin for a total of 12 months (group B) between 1978 and 1984. All (100%) achieved complete initial remission; two patients relapsed and died. Ten patients have remained in relapse‐free survival for 18–67 months (median 32).Though this is not a controlled study, our experience indicates that pre‐ and postradiation chemotherapy is effective in prolonging the disease‐free survival in UNC and may allow a decrease of the radiation tumor dose.
Computed tomography of the abdomen and pelvis: Documentation of tumor response and progression in disseminated prostate cancer
Authors: Winkler Charles F. , Dunnick N. Reed , Eddy Joyce L. , Newman Richard D. , Ihde Daniel C. 
Published: February 2007

AbstractComputed tomography of the abdomen and pelvis has been used to stage early prostatic cancer. We investigated its value in monitoring tumor response in more advanced disease. Serial computed tomography of the abdomen and pelvis was obtained along with multiple other staging tests prior to treatment and at 3‐ to 4‐month intervals thereafter in 32 patients with stage D2 tumor treated initially with combination chemotherapy and with hormones at progression. Pretreatment lymphography with follow‐up abdominal films was also performed. Initial computed tomography of the abdomen and pelvis showed evidence of node metastases in 35% of patients while lymphography was positive in 54%. Among 19 patients with tumor response and 25 with progression, the results of treatment were objectively documented by improvement or worsening, respectively, in a mean of 5.1 and 5.0 other staging tests, exclusive of computed tomography. Computed tomography of the abdomen and pelvis improved in 85% of responding patients examined. Progression was confirmed by worsening of computed tomography in 32%. Although lymphography was often abnormal prior to treatment, in our hands it was not useful in serial monitoring of tumor status. We conclude that serial computed tomography of the abdomen and pelvis, when initially positive, is a useful test to document objectively tumor response and progression in disseminated prostatic cancer.
Modified Capizzi maintenance regimen in children with relapsed acute lymphoblastic leukaemia
Authors: Pinkerton C. R. , Mills S. , Chessells J. M. 
Published: February 2007

AbstractImproved survival of children with acute lymphoblastic leukaemia who relapse during therapy has been reported using the Capizzi maintenance regimen. We have treated ten such patients, without histocompatible donors, with this regimen, which consisted of fortnightly doses of vincristine (1.5 mg/m2) and an escalating dose of intravenous methotrexate (90–470 mg/m2) followed 24 hours later by asparaginase (15,000 units). Remission of disease had been successfully achieved in all patients using conventional therapy prior to the start of maintenance treatment. Cerebro‐spinal fluid concentrations of methotrexate were estimated serially in several patients but remained relatively low despite dose escalation. It appears that additional intrathecal chemotherapy is therefore necessary. Treatment was generally well tolerated but there is concern about the incidence of neurotoxicity in patients who had previously received cranial irradiation and intensive intrathecal therapy. The median duration of bone marrow remission was only 35 weeks (range 18–50). Two patients who had not been receiving IT therapy had early isolated CNS relapses. In conclusion, it appears that contrary to early expectations this treatment approach is unlikly to offer a significantly better outlook for these patients, in whom the chance of early marrow relapse remains high.
Phase II study: The combination DTIC, BCNU, actinomycin D, and vincristine in disseminated malignant melanoma
Authors: Creagan E. T. , Schutt A. J. , Long H. J. , Green S. J. 
Published: February 2007

AbstractThirty patients with disseminated malignant melanoma received the combination DTIC, BCNU, actinomycin D, and vincristine. The objective response rate was 17 percent concomitant with moderate‐to‐severe nausea and vomiting in 80 percent of patients. Hematologic toxicity was transient. In the dose and schedule that we used, the four‐drug regimen does not offer meaningful benefit for patients with advanced melanoma.
Acute myelogenous leukemia following complete remission of small cell carcinoma of the lung
Authors: Yu Peter P. , Waxman Jenny S. , Chahinian A. Philippe , Efremidis Anna P. , Holland James F. 
Published: February 2007

AbstractThe treatment of patients with small cell carcinoma of the lung (SCCL) with combination chemotherapy and radiation has dramatically improved survival in the past decade. With this increased survival, long term complications of therapy are becoming apparent. We report a patient who died of acute myelogenous leukemia (AML) while in complete remission from SCCL. Review of the literature indicates that there may be an increased incidence of AML following successful induction of complete remission in patients with SCCL.
Analysis of prognostic factors in acute lymphoblastic leukemia
Authors: Hammond Denman , Sather Harland , Nesbit Mark , Miller Dennis , Coccia Peter , Bleyer Archie , Lukens John , Siegel Stuart 
Published: February 2007

AbstractChildren with ALL who have a high probability of excellent response, long‐term survival, and cure when treated with widely available standard therapy can be identified at the time of diagnosis. Others can be identified who are at high risk of failure to respond, early relapse, and death. The importance of such prognostic characteristics is so great that they should be considered in the selection of appropriate treatment for each patient. Prognostic factors also must be considered in the design and analysis of clinical trials. All prognostic factors are not equally significant and many of them are closely associated. It is possible to rank them in importance and usefulness by appropriate statistical methods. As additional prognostic factors are identified, and as more effective and more specific therapies are developed, the relative importance of prognostic factors will change.
Clinical and biologic features predict poor prognosis in acute lymphoid leukemias in children and adolescents: A pediatric oncology group review
Authors: Crist W. , Boyett J. , Pullen J. , van Eys J. , Vietti T. 
Published: February 2007

AbstractAlthough the prognosis of children with ALL has improved markedly, approximately one‐half of children continue to relapse. Clinical and biologic features of ALL have been studied at the time of diagnosis and many of these features have been shown to predict the risk of relapse, permitting tailoring of therapy based on relapse hazard. Results of studies of the Pediatric Oncology Group (POG) detailed here demonstrate that high white blood cell (WBC) count at diagnosis, very young or older age within childhood, and the presence of a mediastinal mass or central nervous system leukemia predict a poor prognosis within the context of certain therapies. However, not only age and WBC count, but immunophenotype of ALL as well, were especially predictive of prognosis in these POG studies. The information reviewed here has special importance for the planning of clinical trials for children with ALL.
Predictable risk factors in children with acute lymphoblastic leukemia
Authors: Sakurai Minoru , Kamiya Hitoshi , Kawai Kazuo , Kawasaki Hajime , Komada Yoshihiro , Ido Masaru , Ochiai Hitoshi , Akane Hiroyuki , Sato Kunihiko 
Published: February 2007

AbstractThe predictable prognostic factors were analysed among 174 children with acute lymphoblastic leukemia who were treated during the last ten years under different protocols in one institute. It was confirmed that the children under 1 year of age, or with T‐cell marker, had poor prognosis. The initial WBC of more than 50,000/mm3 was less significant as a predictable risk factor with chemotherapy of the newer protocols. Cell kinetic study was found to be of no more help than the initial WBC, but a more accurate prediction could be obtained by measuring glucocorticoid receptor of leukemic cells. The prognosis was poor among children with initial WBC of more than 50,000/mm3 and receptors of less than 20,000 sites per cell.
Age at diagnosis in childhood acute lymphoblastic leukemia
Authors: Sather Harland N. 
Published: February 2007

AbstractAge at initial diagnosis in ALL has been identified in numerous studies to be an important prognostic factor. Data were examined from a large series of patients entered on ALL clinical trials of the Childrens Cancer Study Group during the period 1972‐1983. These data confirm the importance of age as a prognostic factor and show that even after adjustment for other factors by multivariate analysis, age remains a highly significant predictor of outcome. The data suggest that there are three main age groups with different prognoses: infants (< 1 year at diagnosis), the 1–9 age group, and those 10 or greater. The best prognosis is found in the intermediate age range and the worst in the infant group. While age is presumably a surrogate factor reflecting the effect of factors with more direct and explainable relationships to the disease process, analysis of data in this review and from other recent studies do not yet adequately explain the age effect in terms of other prognostic factors.
United Kingdom medical research council acute lymphoblastic leukaemia (UKALL) trials I‐VIII: Clinical features and results of treatment in four groups of children with adverse prognostic features
Authors: Lilleyman J. S. , Eden O. B. 
Published: February 2007

AbstractFour groups of children with poor‐prognosis disease were selected for study from the Medical Research Council childhood ALL trials. Each group was reviewed for distinguishing clinical features and response to therapy. The four comprised those with a diagnostic white cell count over 50 × 109/1, those with a mediastinal mass, those less than a year old at diagnosis, and those presenting with meningeal involvement. They accounted for 17, 5.3, 2.6, and 3%, respectively, of unselected children with ALL.As expected, all four categories showed significantly inferior relapse‐free survival to the rest, but only in patients with a mediastinal mass and in the under‐1‐year‐olds did a recognisable syndrome emerge clearly associated with other clinical features. These two syndromes, high‐count T‐ALL and high‐count infant null‐ALL, are logical candidates for alternative therapy. Established meningeal disease also continues to present a major therapeutic challenge.
Methotrexate infusions in poor prognosis acute lymphoblastic leukemia in children: I. The Norwegian methotrexate study in acute lymphoblastic leukemia in childhood, august 1975‐December 1980
Authors: Moe Peter Johan , Seip Martin , Finne Per H. , Kolmannskog Svein 
Published: February 2007

AbstractOne hundred fifty‐three children with ALL were diagnosed in Norway in the period August 1975‐December 1980. One hundred thirty‐two of them received 3 infusions of methotrexate as consolidation therapy combined with methotrexate intrathecally as CNS prophylaxis. Eleven (44%) of the total 25 methotrexate cases with WBC above 50 × 109/L were in CCR after 4 1/2‐10 years. Two more cases had discontinued therapy, while in second remission.The event‐free survival of all diagnosed 32 children in Norway with WBC above 50 × 109/L was 37%. Seven infants below the age of 1 year are included in the 32 cases.
Medical oncology manpower supply
Authors: Kennedy B. J. 
Published: February 2007

AbstractAn explosion in the number of trained medical oncologists has led to concern that an overproduction will occur. A survey of 154 medical oncology training programs revealed 767 current trainees—316 first year, 307 second year, and 144 third year. Seventeen programs contained 301 persons (38.5%). After the 1985 certifying examination, 3,659 oncologists were certified. With approximately 750 eligible candidates for each examination, and assuming a 75% pass rate, by 1989 there will be 4,779 certified medical oncologists. By 1990, there will be no deficiency of clinical medical oncologists, but there appears to be a lack of academic oncologists. In order to assure the quality goals of oncology, and in an attempt to meet an adequate supply of medical oncologists, a position statement has been published by the American Society of Clinical Oncology. To avoid an overproduction of medical oncologists, an ongoing assessment of the number needed is warranted.
Treatment of hodgkin's disease stages I and II with chemotherapy alone
Authors: Bubman Itiel , Kirchhoff Louis V. , Morioka Helena , Debellis Normando 
Published: February 2007

AbstractTen previously untreated patients with stages I and II Hodgkin's disease were treated with MOPP chemotherapy alone. Eight of nine evaluable patients went into complete remission (CR). Six remained in CR on the average 82.7 months after induction. Two patients relapsed early and died more than 5 years after entering the study. The patient in whom CR was not achieved died as well. The estimated 10‐year survival rate is 51%. This experience adds to the very small number of reports that have appeared describing the results of treatment of patients with early stage Hodgkin's disease with MOPP alone.
Thyroid cancer following radiotherapy for hodgkin's disease: A case report and review of the literature
Authors: Moroff Saul V. , Fuks Joachim Z. 
Published: February 2007

AbstractImproved survival resulting from advances in therapy in patients with Hodgkin's disease is associated with long‐term morbidity, including the potential for the development of a second solid malignancy. We report a 44‐year‐old man with an unusually aggressive course of thyroid carcinoma 15 years after treatment for Hodgkin's disease. In a review of the English‐language literature, we found 21 cases of thyroid cancer following radiotherapy for Hodgkin's disease, with latency periods ranging from 6 to 48 years. The development of secondary thyroid cancer after high‐dose neck irradiation may be related to hypothyroidism, itself a complication of radiotherapy. Thyroid function should be measured at least once a year in all patients given neck irradiation, with initiation of thyroid hormone replacement if there is evidence of sustained hypothyroidism.
Transcobalamin I as a “marker” for fibrolamellar hepatoma
Authors: Wheeler K. , Pritchard J. , Luck W. , Rossiter M. 
Published: February 2007

AbstractA 12 year old girl with a localised fibrolamellar hepatoma had a raised serum unsaturated vitamin B12 binding capacity (UBBC) and transcobalamin I (TCI) prior to complete resection and chemotherapy. Regular clinical and radiological follow‐up detected no recurrence of her disease, but the UBBC and TCI slowly rose. Local recurrence and pulmonary metastases became detectable 2 1/2 years after diagnosis, 18 months after the UBBC and TCI level became elevated. Measurement of UBBC and TCI can help in the early detection of recurrence long before there is clinical or radiological evidence of recurrent fibrolamellar hepatoma.